Darovasertib

Small molecule

Partialsignal

Evidence outlook · lead readout

DAR-UM-2 (NCT05987332) · Uveal Melanoma

The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.

DAR-UM-2 (NCT05987332): This was a randomized, open-label Phase 2/3 trial with 420 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-04-13. An open-label trial is never graded strong; with a sponsor-reported result, the grade is moderate.

Company guidance: regulatory filing expected H2 2026 (IDEAYA Biosciences, 4 Aug 2026). “Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion expected in H2 2026” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Uveal Melanoma
Phase 2/3 (1)
Uveal Melanoma
Phase 2 (2)
Uveal Melanoma
Other / comorbidity
NCT05187884 · St Vincent's Hospital, Sydney
2022-05-03 – 2025-11-01 · Ocular Melanoma
What this study did
Phase 1/2 (1)
Uveal Melanoma
Phase 1 (1)
Uveal Melanoma
NCT02601378 · Novartis Pharmaceuticals
2016-02-01 – 2022-01-07 · Uveal Melanoma
What this study did

Competitive landscape

This drug's own stage for Uveal Melanoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Darovasertib: this drugPhase 3Small moleculeProtein kinase C (PKC) (inhibitor)Partial signal
NCT05987332: Primary endpoint, PFS by blinded independent central review: median 6.9 vs 3.1 months vs investigator's choice (HR 0.42; 95% CI 0.30-0.59) (IDEAYA, 2026-04-13).
Tebentafusp-Tebn (KIMMTRAK)ApprovedProtein / enzyme therapeuticgp100-HLA-A*02:01 x CD3Partial signal
NCT03070392: Efficacy: Overall Survival (From randomization to the data cut off date of 13-Oct-2020; median follow-up duration was 14.1 months.): Tebentafusp 21.7 Months (95% CI 18.6 to 28.6) | Investigator's Choice 16 Months (95% CI 9.7 to 18.4)
Sturlimogene ErparepvecPhase 2/3Oncolytic virusOncolytic HSV-1 (tumour lysis and immune stimulation)not yet gradedNo reviewed efficacy summary in this indication
RoginolisibPhase 2Small moleculePI3K-deltanot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Darovasertib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
January 2027 (2)
Phase 2/3Uveal MelanomaActive not recruiting
Est. primary completion 2027-01-15 · NCT05987332 · CT.gov ↗
What to watch
Phase 1/2Uveal MelanomaRecruiting
Est. primary completion 2027-01-29 · NCT03947385 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Uveal MelanomaActive not recruiting
Est. primary completion 2027-04-30 · NCT05907954 · CT.gov ↗
What to watch
2030 (1)
October 2030 (1)
Phase 3Uveal MelanomaRecruiting
Est. primary completion 2030-10 · NCT07015190 · CT.gov ↗
What to watch
2034 (1)
March 2034 (1)
Phase 3Uveal MelanomaRecruiting
Est. primary completion 2034-03 · NCT07804186 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 June 2026Topline resultOptimUM-02 complete primary analysis data presented at ASCO
13 April 2026Topline resultOptimUM-02 Phase 2/3 (NCT05987332) met its primary endpoint: PFS by BICR
IDEAYA Biosciences · Source ↗